Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Michael C. Cox"'
Autor:
Marie-Pierre L. Gauthier, Alicia M. Mohr, Russell B. Hawkins, Michael P. Kladde, Maigan A. Brusko, Marvin L. Dirain, Parker Knight, Azra Bihorac, Jaimar Rincon, Ricardo Ungaro, Frederick A. Moore, Lyle L. Moldawer, Todd M. Brusko, Scott C. Brakenridge, Dina C. Nacionales, Michael C. Cox, Philip A. Efron, Rhonda Bacher, Dijoia B Darden
Publikováno v:
Shock
Background Increased circulating myeloid-derived suppressor cells (MDSCs) are independently associated with poor long-term clinical outcomes in sepsis. Studies implicate subsets of MDSCs having unique roles in lymphocyte suppression; however, charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60457279469bfdd46b09674c3fabc071
https://europepmc.org/articles/PMC8019679/
https://europepmc.org/articles/PMC8019679/
Autor:
Leo Mascarenhas, Steven G. DuBois, Steven M. Smith, Mark Reynolds, Catherine M. Albert, Angela M. Feraco, Jessica L Davis, Ramamoorthy Nagasubramanian, Michael C. Cox, Theodore W. Laetsch, Scott Cruickshank, Noah Federman, Erin R. Rudzinski, Brian B. Tuch, Alberto S. Pappo, Kevin Ebata, Brian Turpin, Douglas S. Hawkins
Publikováno v:
The Lancet. Oncology, vol 19, iss 5
BackgroundGene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical mo
Autor:
Steven G. DuBois, Michael J. Nathenson, John F. Deeken, Anna F. Farago, Luis E. Raez, Alberto S. Pappo, Ryma Benayed, Alexander Drilon, Funda Meric-Bernstam, Christina S. Baik, Brian B. Tuch, David M. Hyman, Valentina Boni, Noah Federman, Marcia S. Brose, Ulrik Lassen, Douglas S. Hawkins, Kevin Ebata, Nora Ku, Jordan Berlin, Scott Cruickshank, Leo Mascarenhas, Theodore W. Laetsch, Brian Turpin, George D. Demetri, Afshin Dowlati, Patrick C. Ma, Shivaani Kummar, David S. Hong, Robert C. Doebele, Jaclyn F. Hechtman, Ramamoorthy Nagasubramanian, Davendra Sohal, Matthew H. Taylor, Michael C. Cox, Wafik S. El-Deiry, Marc Ladanyi, Erin R. Rudzinski
Publikováno v:
The New England journal of medicine, vol 378, iss 8
BackgroundFusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumor
Publikováno v:
Cancer Research. 81:1481-1481
DAY101 (formerly TAK-580) is an oral, CNS-penetrant, selective small molecule pan-RAF kinase inhibitor that is equipotent against BRAF V600E, wildtype BRAF, and CRAF and can inhibit both RAF monomers and dimers, including BRAF fusions. KIAA1549:BRAF
Autor:
Robert C. Doebele, Anna F. Farago, H. A. Burris, James J. Lee, Todd M. Bauer, Scott Cruickshank, Michael C. Cox, Matthew H. Taylor, Marcia S. Brose, Alice T. Shaw, Steven J. Smith, Afshin Dowlati, David S. Hong, S Montez, Brian B. Tuch, Funda Meric-Bernstam, Kevin Ebata
Publikováno v:
Annals of Oncology
Background NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective ATP-competitive inhibitor of TRK kinases and has demonstrated activity in patients with tumours harbo
Autor:
Steven G. DuBois, Anna F. Farago, Birgit Geoerger, Juneko E. Grilley-Olson, Nora Ku, Shivani Nanda, Davendra Sohal, David S. Hong, Alexander Drilon, Barrett H. Childs, David S. Ziegler, Cornelis M. van Tilburg, Francois P. Doz, Michael C. Cox
Publikováno v:
Journal of Clinical Oncology. 37:2006-2006
2006 Background: TRK fusions are oncogenic drivers of a variety of cancers, many of which can involve the central nervous system (CNS). Larotrectinib is an FDA-approved selective TRK inhibitor for the treatment of TRK fusion cancer (Drilon et al, NEJ
Autor:
Theodore W. Laetsch, Noah Federman, Barrett H. Childs, Leo Mascarenhas, Catherine M. Albert, Alberto S. Pappo, Shivani Nanda, Brian Turpin, Birgit Geoerger, Steven G. DuBois, Michela Casanova, Sheri L. Spunt, Neerav Shukla, Daniel Orbach, Stefan S. Bielack, Hope Qamoos, Ramamoorthy Nagasubramanian, Cornelis M. van Tilburg, Michael C. Cox
Publikováno v:
Journal of Clinical Oncology. 37:10010-10010
10010 Background: TRK fusions involving NTRK1, NTRK2, and NTRK3 genes have been identified in a broad range of pediatric and adult malignancies. Larotrectinib, a highly-selective oral TRK inhibitor, was well tolerated and showed encouraging antitumor
Autor:
C.M. van Tilburg, Jordan Berlin, D.S.W. Tan, D-Y. Oh, Leo Mascarenhas, Russell J. Schilder, François Doz, Raymond S. McDermott, Steven G. DuBois, Shivaani Kummar, David S. Hong, Michael C. Cox, A. Drilon, Catherine M. Albert, Birgit Geoerger, Noah Federman, Scott Cruickshank, Nora Ku, Ulrik Lassen, Stefan S. Bielack
Publikováno v:
Annals of Oncology. 29:viii133
Autor:
Ramamoorthy Nagasubramanian, Stefan S. Bielack, Sheri L. Spunt, Alberto S. Pappo, Steven G. DuBois, Michael C. Cox, Theodore W. Laetsch, Cornelis M. van Tilburg, Maria Soledad Gallego Melcon, Catherine M. Albert, Gianni Bisogno, Julia C. Chisholm, Michela Casanova, Douglas S. Hawkins, Leo Mascarenhas, Birgit Geoerger, Neerav Shukla, Brian Turpin, Francois P. Doz, Noah Federman
Publikováno v:
Annals of Oncology. 28:v139
TPS10577 Background: Neurotrophin ligands and their receptors TRKA, TRKB, and TRKC (encoded by NTRK1, NTRK2, and NTRK3) are important for growth regulation, differentiation and survival of neurons. Translocations involving the NTRK1/2/3 kinase domain
Publikováno v:
Current Oncology Reports. 7:215-219
Prostate cancer is the leading cause of cancer diagnosis in men and the second leading cause of cancer-related death. Androgen ablation is effective initially, and progression of disease often occurs in many patients. Although recent reports have not